Lytgobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(9 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(12 years from now)

Lytgobi is owned by Taiho Oncology.

Lytgobi contains Futibatinib.

Lytgobi has a total of 2 drug patents out of which 0 drug patents have expired.

Lytgobi was authorised for market use on 30 September, 2022.

Lytgobi is available in tablet;oral dosage forms.

Lytgobi can be used as method of treating intrahepatic cholangiocarcinoma.

Drug patent challenges can be filed against Lytgobi from 2026-09-30.

The generics of Lytgobi are possible to be released after 31 March, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027
Orphan Drug Exclusivity (ODE) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 2026-09-30

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma


More Information on Dosage

LYTGOBI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic